March 22 2016 Issue

1) Statin pretreatment is associated with better outcomes in large-artery atherosclerotic stroke2) e-Pearl topic: Fatal familial insomnia3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Georgios Tsivgoulis about his paper on how statin pretreatment is associated with better outcome in large-artery atherosclerotic stroke. Dr. Steve O'Donnell is reading our e-Pearl of the week about fatal familial insomnia. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Emmanuelle Waubant about the topic of vitamin D in pediatric multiple sclerosis. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Tsivgoulis serves as Associate Editor for Neurosonology; serves as an editorial board member of Journal of Neuroimaging; and receives research support from the European Regional Development Fund.Dr. O'Donnell serves on the editorial team for the Neurology Resident and Fellow Section.Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada.Dr. Waubant serves on the scientific advisory board for Novartis; serves as an editorial board member of Annals of Clinical and Translational Neurology; is an ad hoc consultant for Roche and MedDay; received funding for travel for one educational physician lecture from Genentech, Inc.; receives royalties from the publication of the book Demyelinating disorders of the central nervous system in childhood; receives research support for trials of ocrelizumab in PPMS (Roche), and fingolimod in pediatric MS (Novartis); receives research support from the National Multiple Sclerosis Society, the Race to Erase MS and NIH.